Skip to main content
SpringerLink
Log in

TBK1: a new target for overcoming cancer immunotherapy resistance

  • Research Highlight
  • Published:
Science China Life Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Morad, G., Helmink, B.A., Sharma, P., and Wargo, J.A. (2022). Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185, 576.

    Article  CAS  PubMed  Google Scholar 

  • Runde, A.P., Mack, R., S.j., P.B., and Zhang, J. (2022). The role of TBK1 in cancer pathogenesis and anticancer immunity. J Exp Clin Cancer Res 41, 135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun, Y., Revach, O., Anderson, S., Kessler, E.A., Wolfe, C.H., Jenney, A., Mills, C.E., Robitschek, E.J., Davis, T.G.R., Kim, S., et al. (2023). Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature 615, 158–167.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Taft, J., Markson, M., Legarda, D., Patel, R., Chan, M., Malle, L., Richardson, A., Gruber, C., Martín-Fernández, M., Mancini, G.M.S., et al. (2021). Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death. Cell 184, 4447–4463.e20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu, D., Jin, T., Zhu, H., Chen, H., Ofengeim, D., Zou, C., Mifflin, L., Pan, L., Amin, P., Li, W., et al. (2018). TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell 174, 1477–1491.e19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgement

This work was supported by the National Key Research and Development Program of China (2021YFA1101000, 2022YFA1105200), the National Natural Science Foundation of China (82041009, 32125016, U20A20393, 31925013), Zhejiang Natural Science Fund (LD19C070001) and Gusu Innovation Leading Talent Program (ZXL2022505).

Author information

Authors and Affiliations

  1. Institutes of Biology and Medical Science, Soochow University, Suzhou, 215123, China

    Jizhong Guan & Fangfang Zhou

  2. MOE Laboratory of Biosystems Homeostasis and Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, 310058, China

    Long Zhang

Authors
  1. Jizhong Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Long Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fangfang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Long Zhang or Fangfang Zhou.

Ethics declarations

The author(s) declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guan, J., Zhang, L. & Zhou, F. TBK1: a new target for overcoming cancer immunotherapy resistance. Sci. China Life Sci. 67, 217–218 (2024). https://doi.org/10.1007/s11427-023-2395-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11427-023-2395-y

Search

Navigation